Skip to main content
SpringerLink
Log in

ICOS costimulation in inflammatory bowel disease

  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

For years, medical researchers have striven to develop selective immunotherapies that could specifically ameliorate pathogenic immune responses without immunocompromising the patient. Blockade of many known receptors on T cells can inhibit the initiation of immune responses. However, this approach is problematic in that it is not possible to predict the onset of disease in patients. Current immunotherapies are unsatisfactory for the sporadic exacerbating type of diseases such as multiple sclerosis and inflammatory bowel disease (IBD), because they require either long-term treatment or acute treatment with high-dose immuno-suppressants. With regard to this issue, the inducible and inflammatory site-specific molecule, inducible costimulator (ICOS), may be particularly useful as an ideal targeting molecule for the strategy of treatment of human IBD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1995; 325:928–37.

    Article  Google Scholar 

  2. Fiocchi C. Inflammatory bowel disease—etiology and pathogenesis. Gastroenterology 1998;115:182–205.

    Article  PubMed  CAS  Google Scholar 

  3. Fuss IJ, Neurath M, Boirvant M, Klein JS, de la Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261–70.

    PubMed  CAS  Google Scholar 

  4. Parronchi P, Romagnani P, Annuziato F, Sampognaro S, Becchio A, Giannarini L, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn’s disease. Am J Pathol 1997;150:823–32.

    PubMed  CAS  Google Scholar 

  5. Hammer RE, Maika SD, Richardson JA, Tang YP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human b2m: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099–112.

    Article  PubMed  CAS  Google Scholar 

  6. Watanabe M, Ueno Y, Yajima T, Okamoto S, Hayashi T, Yamazaki M, et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med 1998; 187:389–402.

    Article  PubMed  CAS  Google Scholar 

  7. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horvak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253–61.

    Article  PubMed  CAS  Google Scholar 

  8. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1003;75:263–74.

    Article  Google Scholar 

  9. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bahn AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993;75:275–82.

    Article  CAS  Google Scholar 

  10. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Thl responses prevents inflammatory bowėl disease in scid mice reconstituted with CD45Rbhi CD4+ T cells. Immunity 1994;l:553–62.

    Article  Google Scholar 

  11. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994;15:321–31.

    Article  PubMed  CAS  Google Scholar 

  12. Chambers CA. The expanding world of co-stimulation: the two-signal model revised. Trends Immunol 2001;22:217–23.

    Article  PubMed  CAS  Google Scholar 

  13. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001;2:203–9.

    Article  PubMed  CAS  Google Scholar 

  14. Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999;163:1704–10.

    PubMed  CAS  Google Scholar 

  15. Tada Y, Nagasawa K, Ho A, Morito F, Ushiyama O, Suzuki N, et al. CD28-deficient mice are highly resistant to collagen-induced arthritis. J Immunol 1999;162:203–98.

    PubMed  CAS  Google Scholar 

  16. Nakazawa A, Watanabe M, Kanai T, Yajima T, Yamazaki M, Ogata H, et al. Functional expression of costimulatory molecule CD86 on epithelial cells in the inflamed colonic mucosa. Gastroenterology 1999;117:536–45.

    Article  PubMed  CAS  Google Scholar 

  17. Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001;22:217–23.

    Article  PubMed  CAS  Google Scholar 

  18. Hutloff A, Dittrich AM, Beier KC, Eijaschewitsch B, Kraft R, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (Lond) 1999; 397:263–6.

    Article  CAS  Google Scholar 

  19. Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature (Lond) 1999;402:827–32.

    Article  CAS  Google Scholar 

  20. Mages HW, Hutloff A, Heuck C, Buchner K, Himmelbauer H, Oliveri F, et al. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol 2000;30:1040–7.

    Article  PubMed  CAS  Google Scholar 

  21. Tamatani T, Tezuka K, Hanzawa-Higuchi N. AILIM/ICOS: a novel lymphocyte adhesion molecule. Int Immunol 2000;12: 51–5.

    Article  PubMed  CAS  Google Scholar 

  22. Peach RJ, Bajorath J, Brady W, Leytze G, Greene J, Naenura J, et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J Exp Med 1994;180:2049–58.

    Article  PubMed  CAS  Google Scholar 

  23. Coyle AJ, Lehar S, Lloyd C, Tian J, Delaney T, Manning S, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000;13:95–105.

    Article  PubMed  CAS  Google Scholar 

  24. McAdam AJ, Chang TT, Lumelsky AE, Greenfield EA, Boussiotis VA, Duke-Cohan JS, et al. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4(+) T cells. J Immunol 2000;165:5035–40.

    PubMed  CAS  Google Scholar 

  25. Dong C, Juedes AE, Tamann UA, Shresta S, Allison JP, Ruddle NH, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (Lond) 2001;409:97–101.

    Article  CAS  Google Scholar 

  26. Tafuri A, Shahinian A, Bladt F, Yoshinaga SK, Jordana M, Wakeham A, et al. ICOS is essential for effective T-helper-cell responses. Nature (Lond) 2001;409:105–9.

    Article  CAS  Google Scholar 

  27. McAdam AJ, Greenwald RJ, Levin MA, Chernova T, Malenkovich N, Ling V, et al. The ICOS molecule is critical for CD40-mediated antibody class switching. Nature (Lond) 2001; 409:105–9.

    Article  Google Scholar 

  28. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tygat GN, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129–35.

    Article  PubMed  Google Scholar 

  29. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997;337:1029–35.

    Article  PubMed  CAS  Google Scholar 

  30. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–405.

    Article  PubMed  CAS  Google Scholar 

  31. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric and TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effectors functions. Cytokine 1995;7:251–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Hepatology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

    Takanori Kanai

  2. Department of Molecular Immunology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan

    Teruji Totsuka & Mamoru Watanabe

  3. Pharmaceutical Frontier Research Laboratories, JT, Yokohama, Japan

    Katsunari Tezuka

Authors
  1. Takanori Kanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teruji Totsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsunari Tezuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mamoru Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanai, T., Totsuka, T., Tezuka, K. et al. ICOS costimulation in inflammatory bowel disease. J Gastroenterol 37 (Suppl 14), 78–81 (2002). https://doi.org/10.1007/BF03326419

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03326419

Keywords

Search

Navigation